Today Phlow Corp. released the following statement on the introduction of S.2740, the Promoting Readiness and Ensuring Proper Active Pharmaceutical Ingredient Reserves of Essential Medicines (PREPARE) Act of 2021 in the United States Senate.

Phlow recognizes and supports the introduction of the “PREPARE Act.” When enacted, this legislation will ensure a reliable supply of essential medicines for all Americans. Essential medicines, as published by the Food and Drug Administration (FDA) last year, are the priority medications necessary to sustain the health of the American population or that are medically necessary to have available at all times. The intent of the PREPARE Act aligns with Phlow’s commitment to build a stable, reliable domestic supply chain and stockpile for essential medicines.

Phlow appreciates the bipartisan leadership and forward-thinking of the sponsors: Senator Sherrod Brown (D-OH) and Senator Bill Cassidy, MD (R-LA). The advancement of the “PREPARE Act” is an important step that further demonstrates the focus, dedication, and continued effort of the U.S. Government to end essential medicine shortages.

This bill is a strong indication that the U.S. Government recognizes the importance of enhancing domestic manufacturing, as well as providing diversity in the essential medicine supply chain. Phlow has long supported the need for a national strategic active pharmaceutical ingredient reserve, as well as other production facilities to ensure all Americans have an uninterrupted supply of affordable essential medicines, including medical countermeasures and critical pharmaceutical inputs.

About Phlow

Phlow Corp. is a trailblazing, essential medicines impact company that is reimagining essential medicines from start to finish through the use of flow chemistry and other advanced development and manufacturing processes. Everything Phlow does is designed to promote access to affordable, high-quality essential medicines for all Americans. Phlow is working to provide a solution to the broken essential medicines supply chain by establishing a resilient end-to-end solution that is U.S.-based, comprehensive, and fully integrated. With the support of an industry leading team, experienced strategic partners, and established relationships at the policy, regulatory, and federal levels, Phlow will manufacture active pharmaceutical ingredients (APIs) and finished pharmaceutical products domestically for essential medicines critical to the nation’s healthcare. Through the use of continuous-flow processes and other green chemistry approaches, Phlow is able to reduce costs and waste, improve quality and yield, and offer a more environmentally friendly alternative to batch manufacturing.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210915006062/en/